Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 7/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043612 | 0.82 | CACNA1B (0.53) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL15043596 | 0.81 | CACNA1B (0.51) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL19857280 | 0.80 | CACNA1B (0.44) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL15043597 | 0.79 | CACNA1B (0.50) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL21441627 | 0.79 | CACNA1B (0.50) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL15444037 | 0.79 | CACNA1B (0.50) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL15043607 | 0.78 | CACNA1B (0.49) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL22602378 | 0.78 | CACNA1B (0.56) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL15043595 | 0.77 | CACNA1B (0.48) | CACNA1BAPBA1ALDH1A1TP53HPGD | |
| SCHEMBL21425541 | 0.75 | CACNA1B (0.58) | CACNA1BAPBA1ALDH1A1TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180043033-A1 | AMATOXIN-ANTIBODY CONJUGATES | HEIDELBERG PHARMA GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180043033-A1 | AMATOXIN-ANTIBODY CONJUGATES | C3AR1, ANTXR2, MTX2 | CACNA1B 2953/4885APBA1 192/4885ALDH1A1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.